Cell and gene therapies
-
Genomics chair sounds warning bell
- 01 Sep 2021
Australian policymakers need to act fast to stay ahead of the social conversation, says InGeNA’s David Bunker.
Read more -
Novartis boss laments Zolgensma delay
- 23 Jun 2021
Public funding of new gene therapies takes too long, says Richard Tew, revealing Zolgensma has been in reimbursement processes almost 18 months.
Read more -
Need for ‘fast learning’ Australian HTA
- 21 Jun 2021
Biointelect’s David Grainger says with 40 gene therapies on the horizon, Australia’s HTA needs to be more flexible and comfortable with uncertainty.
Read more -
Need for change in cost comparators
- 18 Jun 2021
Janssen MD says the use of lowest cost comparators in the assessment of transformative medicines can be like comparing a Tesla to a horse.
Read more -
Gene ‘cure’ shines in Vertex pipeline
- 16 Jun 2021
As Vertex goes into stakeholder talks for Trikafta, the outcome may have longer-term ramifications for a promising gene therapy ‘cure’ in its pipeline.
Read more -
Aussies access Biogen ALS drug
- 26 May 2021
Biogen is looking to provide early and compassionate access to some ALS patients later this year, with Australians in the line-up.
Read more -
Is Europe ready for gene therapies?
- 26 May 2021
Novartis report questions whether Europe’s regulator is ready for gene therapies as the EMA considers bluebird bio’s cALD gene therapy.
Read more -
Former Bayer ANZ access leader joins global bio-revolution
- 21 May 2021
Matt Slabbert left Australia last year for a top global role for Bayer in Germany. Nine months later, he’s moving into an exciting new public affairs position.
Read more